- Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

HiFiBiO Therapeutics concludes first cohort of Covid-19 antibody study

HFB30132A can potentially neutralise live virus infection in vitro and in vivo. Credit: Gerd Altmann on Pixabay.